Veronica Venafra

This study investigates how kinase inhibitors reshape the immunopeptidome in CML by altering HLA-I peptide presentation through three molecular mechanisms.

PatientProfiler integrates multi-omic data to generate patient-specific mechanistic models and prognostic biomarkers for breast cancer.

NetworkCommons integrates prior knowledge, omics data, and network inference methods to build and evaluate context-specific biological networks.

The paper identifies BCR::ABL1-independent survival mechanisms in CML using phosphoproteomics and computational analysis, highlighting FLT3 as a therapeutic target for TKI-resistant cases.

SignalingProfiler 2.0 integrates proteogenomic data with causal networks to generate mechanistic signaling models that recapitulate drug-perturbed phenotypes in breast cancer cells.